Skip to main content

Table 1 Patient characteristics

From: Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

Characteristic Median (range) or number of patients (%)
Age at diagnosis, years 58.7 years (45.6–84.1)
Gender
 -Male 16 (69.6%)
 -Female 7 (30.4%)
Cancer type
 -NSCLC 16 (69.6%)
 -RCC 4 (17.4%)
 -Melanoma 3 (13.0%)
ECOG Performance Status
 -0 5 (21.7%)
 -1 12 (52.2%)
 -2 6 (26.1%)
Smoking history
 -Current 4 (17.4%)
 -Former 8 (34.8%)
 -Never 10 (13.0%)
 -Unknown 1 (4.4%)
Immune Checkpoint Inhibitor
 -Nivolumab 22 (95.7%)
 -Pembrolizumab 1 (4.3%)
Previous lines of therapy
 -0–1 11 (47.8%)
 -2–3 7 (30.4%)
 -> 3 5 (21.7%)
Molecular aberrationa
 -KRAS mutation 7 (30.4%)
 -BRAF mutation 2 (8.7%)
 -EGFR mutation 1 (4.4%)
 -NRAS mutation 1 (4.4%)
 -TP53 1 (4.4%)
 -Wildtype 6 (26.1%)
PD-L1 Expression
 -0% 1 (4.4%)
 -1–5% 1 (4.4%)
 -5–10% 1 (4.4%)
 -10–20% 1 (4.4%)
 -100% 1 (4.4%)
 -unknown 18 (78.3%)
  1. aAnalysis by next-generation sequencing (Oncomine solid tumor panel)